L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, issue.2, pp.87-108, 2012.

N. B. Leighl, Treatment paradigms for patients with metastatic nonsmall-cell lung cancer: first-, second-, and third-line, Curr Oncol, vol.19, issue.1, pp.52-58, 2012.

G. V. Scagliotti, P. Parikh, J. Von-pawel, B. Biesma, J. Vansteenkiste et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, vol.26, issue.21, pp.3543-51, 2008.

J. H. Schiller, D. Harrington, C. P. Belani, C. Langer, A. Sandler et al.,

, Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer, N Eng J Med, vol.346, issue.2, pp.92-100, 2002.

,

T. F. Gajewski, H. Schreiber, and Y. X. Fu, Innate and adaptive immune cells in the tumor microenvironment, Nat Immunol, vol.14, issue.10, pp.1014-1036, 2013.

,

R. D. Schreiber, L. J. Old, and M. J. Smyth, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, vol.331, issue.6024, pp.1565-70, 2011.

G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, vol.3, issue.11, pp.991-999, 2002.

M. D. Vesely, M. H. Kershaw, R. D. Schreiber, and M. J. Smyth, Natural innate and adaptive immunity to cancer, Ann Rev Immunol, vol.29, pp.235-71, 2011.

,

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, issue.4, pp.252-64, 2012.

,

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Eng J Med, vol.373, issue.17, pp.1627-1666, 2015.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crino, W. E. Eberhardt et al., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Eng J Med, vol.373, issue.2, pp.123-158, 2015.

S. L. Topalian, C. G. Drake, and D. M. Pardoll, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, vol.27, issue.4, pp.450-61, 2015.

S. Gettinger and R. S. Herbst, B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction, Cancer J, vol.20, issue.4, pp.281-290, 2014.

J. R. Brahmer, S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Eng J Med, vol.366, issue.26, pp.2455-65, 2012.

S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Eng J Med, vol.366, issue.26, pp.2443-54, 2012.

R. S. Herbst, J. C. Soria, M. Kowanetz, G. D. Fine, O. Hamid et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, pp.563-570, 2014.

,

L. Galluzzi, A. Buque, O. Kepp, L. Zitvogel, and G. Kroemer, Immunogenic cell death in cancer and infectious disease, Nat Rev Immunol, vol.17, issue.2, pp.97-111, 2017.

D. Maio, M. Lama, N. Morabito, A. Smit, E. F. Georgoulias et al., Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials, Euro J Cancer, vol.46, issue.4, pp.735-778, 2010.

,

L. H. Schwartz, S. Litiere, E. De-vries, R. Ford, S. Gwyther et al., RECIST 1.1-Update and clarification: From the RECIST committee, Euro J Cancer, vol.62, pp.132-139, 2016.

R. S. Herbst, P. Baas, D. W. Kim, E. Felip, J. L. Perez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 2016.

L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, issue.2, pp.87-108, 2012.

E. Giroux-leprieur, C. Dumenil, J. C. , G. V. Dumoulin, J. Labrune et al., Immunotherapy revolutionises non-smallcell lung cancer therapy: results, perspectives and new challenges, Eur J Cancer Oxf Engl, vol.78, pp.16-23, 1990.

R. Califano, K. Kerr, R. D. Morgan, L. Russo, G. Garassino et al., Immune checkpoint blockade: a new era for non-small cell lung cancer, Curr Oncol Rep, vol.18, issue.9, p.59, 2016.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, vol.373, issue.17, pp.1627-1639, 2015.

R. S. Herbst, P. Baas, D. Kim, E. Felip, J. L. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond Engl, vol.387, pp.1540-1550, 2016.

L. P. Diggs and E. C. Hsueh, Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response, Biomark Res, vol.5, p.12, 2017.

C. Grigg and N. A. Rizvi, PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?, J Immunother Cancer, vol.4, p.48, 2016.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, vol.10, pp.1823-1833, 2016.

J. M. Taube, A. Klein, J. R. Brahmer, H. Xu, X. Pan et al., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res Off J Am Assoc Cancer Res, vol.20, pp.5064-5074, 2014.

E. B. Garon, N. A. Rizvi, R. Hui, N. Leighl, A. S. Balmanoukian et al., Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, vol.372, issue.21, pp.2018-2028, 2015.

R. Weber, V. Fleming, X. Hu, V. Nagibin, C. Groth et al., Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors, Front Immunol, vol.9, p.1310, 2018.

B. Weide, A. Martens, J. C. Hassel, C. Berking, M. A. Postow et al., Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin Cancer Res Off J Am Assoc Cancer Res, vol.22, issue.22, pp.5487-5496, 2016.

A. C. Huang, M. A. Postow, R. J. Orlowski, R. Mick, B. Bengsch et al., Lung cancer epidemiology: contemporary and future challenges worldwide, Ann Transl Med, vol.4, issue.8, 2016.

T. Donnem, Stromal CD8 + T-cell density-a promising supplement to TNM staging in non-small cell lung cancer, Clin. Cancer Res, vol.21, pp.2635-2643, 2015.

Z. Gatalica, Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type, Cancer Epidemiol. Prev. Biomark, vol.23, pp.2965-2970, 2014.

S. C. Azoury, D. M. Straughan, and V. Shukla, Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets, vol.15, pp.452-62, 2015.

M. Reck, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med, vol.375, pp.1823-1833, 2016.

R. S. Herbst, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, pp.1540-1550, 2016.

E. B. Garon, Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med, vol.372, 2015.

H. Borghaei, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med, vol.373, pp.1627-1639, 2015.

J. Brahmer, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med, vol.373, pp.123-135, 2015.

. Hellmann, Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer, Cancer Cell, vol.33, pp.843-852, 2018.

L. Fehrenbacher, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, vol.387, pp.1837-1846, 2016.

R. J. Motzer, Nivolumab versus everolimus in advanced renal-cell carcinoma, N. Engl. J. Med, vol.373, pp.1803-1813, 2015.

F. S. Hodi, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med, pp.711-723, 2010.

D. P. Carbone, First-Line nivolumab in stage IV or recurrent non-small-cell lung cancer, N. Engl. J. Med, vol.376, pp.2415-2426, 2017.

J. Sunshine and J. M. Taube, PD-1/PD-L1 inhibitors, Curr. Opin. Pharmacol, vol.23, pp.32-38, 2015.

M. Ayers, IFN-?-related mRNA profile predicts clinical response to PD-1 blockade, J. Clin. Invest, vol.127, pp.2930-2940, 2017.

B. Wallden, Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx analysis system, J. Clin. Oncol, vol.34, issue.15_suppl, pp.3034-3034, 2016.

Q. Wang and X. Wu, Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment, Int Immunopharmacol, vol.46, pp.210-219, 2017.

P. C. Tumeh, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, pp.568-571, 2014.

M. W. Teng, S. F. Ngiow, A. Ribas, and M. J. Smyth, Classifying cancers based on T-cell infiltration and PD-L1, Cancer Res, vol.75, pp.2139-2145, 2015.

Y. Wan, G. I. Allen, and Z. Liu, TCGA2STAT: simple TCGA data access for integrated statistical analysis in R, Bioinformatics, vol.32, pp.952-954, 2016.

A. H. Scheel, Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas, Mod. Pathol, vol.29, pp.1165-1172, 2016.

P. Bankhead, QuPath: open source software for digital pathology image analysis. bioRxiv. 6 mars, p.99796, 2017.

N. L. Bray, H. Pimentel, P. Melsted, and L. Pachter, Near-optimal probabilistic RNAseq quantification, Nat. Biotechnol, vol.34, p.525, 2016.

M. I. Love, W. Huber, and S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, vol.15, p.550, 2014.

E. Y. Chen, Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool, BMC Bioinform, vol.14, p.128, 2013.

M. V. Kuleshov, Enrichr: a comprehensive gene set enrichment analysis web server 2016 update, Nucleic Acids Res, vol.44, pp.90-97, 2016.

E. A. Eisenhauer, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer, vol.45, pp.228-247, 2009.

J. Budczies, Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization, PLOS ONE, vol.7, p.51862, 2012.

A. Prat, Immune-related gene expression profiling after pd-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma, Cancer Res, vol.77, pp.3540-3550, 2017.

T. Tokito, Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non?small cell lung cancer patients receiving concurrent chemoradiotherapy, Eur. J. Cancer, vol.55, pp.7-14, 2016.

Y. Zhang, Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma, OncoTargets Ther, vol.12, pp.567-73

Y. Chen, C. Mu, and J. Huang, Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-followup study, Tumori, vol.98, pp.751-755, 2012.

, Prognostic and predictive role of CD8 and PD-L1 determination in lung

J. Fumet,

C. Mu, J. Huang, Y. Chen, C. Chen, and X. Zhang, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Med Oncol, vol.28, pp.682-688, 2011.

L. H. Schmidt, PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups, PLOS ONE, vol.10, p.136023, 2015.

J. M. Boland, Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung, Clin. Lung Cancer, vol.14, pp.157-163, 2013.

M. Zhang, PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis, Sci. Rep, vol.7, p.10255, 2017.

K. I. Al-shibli, Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer, Clin. Cancer Res, vol.14, pp.5220-5227, 2008.

M. Ilie, Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Ann. Oncol, vol.27, pp.147-153, 2016.

A. Gagné, Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays: impact of the architecture pattern and the number of cores, Am. J. Surg. Pathol, vol.42, p.687, 2018.

F. R. Hirsch, PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project, J. Thorac. Oncol, vol.12, pp.208-222, 2017.

S. Gadgeel, 1296O Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L + NSCLC: results from the randomized OAK study, Disponible sur, vol.28, 2017.

J. Konishi, B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression, Clin. Cancer Res, vol.10, pp.5094-5100, 2004.

G. Mazzaschi, Low PD-1 expression in cytotoxic CD8+ tumor infiltrating lymphocytes confers an immune privileged tissue microenvironment in NSCLC with a prognostic and predictive value, Clin. Cancer Res, vol.2156, p.2017, 2017.

A. C. Huang, T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, vol.545, pp.60-65, 2017.

D. T. Le, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med, vol.372, pp.2509-2520, 2015.

L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, pp.87-108, 2012.

E. Giroux-leprieur, C. Dumenil, J. C. , G. V. Dumoulin, J. Labrune et al., Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges, Eur J Cancer Oxf Engl, vol.78, pp.16-23, 1990.

R. Califano, K. Kerr, R. D. Morgan, L. Russo, G. Garassino et al., Immune checkpoint blockade: a new era for non-small cell lung cancer, Curr Oncol Rep, vol.18, pp.59-63, 2016.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, vol.373, pp.1627-1666, 2015.

R. S. Herbst, P. Baas, D. Kim, E. Felip, J. L. Gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet Lond Engl, vol.387, pp.1540-50, 2016.

A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet Lond Engl, vol.389, pp.255-65, 2017.

S. H. Lim, J. Sun, S. Lee, J. S. Ahn, K. Park et al., Pembrolizumab for the treatment of non-small cell lung cancer, Expert Opin Biol Ther, vol.16, pp.397-406, 2016.

L. P. Diggs and E. C. Hsueh, Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response, Biomark Res, vol.5, pp.12-20, 2017.

C. Grigg and N. A. Rizvi, PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?, J Immunother Cancer, vol.4, pp.48-54, 2016.

J. M. Taube, A. Klein, J. R. Brahmer, H. Xu, X. Pan et al., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res, vol.20, pp.5064-74, 2014.

E. B. Garon, N. A. Rizvi, R. Hui, N. Leighl, A. S. Balmanoukian et al., Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, vol.372, pp.2018-2046, 2015.

N. A. Rizvi, J. Mazi-eres, D. Planchard, T. E. Stinchcombe, G. K. Dy et al., Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol, vol.16, pp.257-65, 2015.

L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste et al., Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet Lond Engl, vol.387, pp.1837-1883, 2016.

N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, pp.124-132, 2015.

H. Rizvi, F. Sanchez-vega, L. K. Chatila, W. Jonsson, P. Halpenny et al., Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing, J Clin Oncol, vol.36, pp.633-674, 2018.

D. P. Carbone, M. Reck, L. Paz-ares, B. Creelan, L. Horn et al., Firstline nivolumab in stage IV or recurrent non-small-cell lung cancer, N Engl J Med, vol.376, pp.2415-2441, 2017.

L. H. Schwartz, S. Liti-ere, E. De-vries, R. Ford, S. Gwyther et al., RECIST 1.1-Update and clarification: frrom the RECIST committee, Eur J Cancer Oxf Engl, vol.62, pp.132-139, 1990.

J. Budczies, F. Klauschen, B. V. Sinn, B. Gyo-rffy, W. D. Schmitt et al., Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization, PloS One, vol.7, p.51862, 2012.

J. Friedman, T. Hastie, and R. Tibshirani, Regularization paths for generalized linear models via coordinate descent, J Stat Softw, vol.33, pp.1-22, 2010.

L. Kang, W. Chen, N. A. Petrick, and B. D. Gallas, Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach, Stat Med, vol.34, pp.685-703, 2015.

B. Gyorffy, G. Bottai, A. Nagy, L. Pusztai, and L. Santarpia, Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability, J Clin Oncol, vol.35, pp.1096-1096, 2017.

M. Angelova, P. Charoentong, H. Hackl, M. L. Fischer, R. Snajder et al., Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy, Genome Biol, vol.16, pp.64-70, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01149718

C. Liu, W. Peng, C. Xu, Y. Lou, M. Zhang et al., BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice, Clin Cancer Res, vol.19, pp.393-403, 2013.

W. Peng, J. Q. Chen, C. Liu, S. Malu, C. Creasy et al., Loss of PTEN promotes resistance to T cell-mediated immunotherapy, Cancer Discov, vol.6, pp.202-218, 2016.

M. D. Hellmann, T. Nathanson, H. Rizvi, B. C. Creelan, F. Sanchez-vega et al., Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer, Cancer Cell, vol.33, pp.843-852, 2018.

A. Snyder, T. Nathanson, S. A. Funt, A. Ahuja, B. Novik et al., Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multiomic analysis, PLoS Med, vol.14, p.1002309, 2017.

D. Miao, C. A. Margolis, W. Gao, M. H. Voss, W. Li et al., Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma, Science, vol.359, pp.801-807, 2018.

M. Jamal-hanjani, G. A. Wilson, N. Mcgranahan, N. J. Birkbak, T. Watkins et al., Tracking the evolution of non-small-cell lung cancer, N Engl J Med, vol.376, pp.2109-2130, 2017.

P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. Taylor et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, pp.568-71, 2014.

R. Bibliographiques,

I. A. Adzhubei, S. Schmidt, L. Peshkin, V. E. Ramensky, and A. Gerasimova, A method and server for predicting damaging missense mutations, Nat. Methods, vol.7, pp.248-249, 2010.

I. Adzhubei, D. M. Jordan, and S. R. Sunyaev, Predicting functional effect of human missense mutations using PolyPhen-2, Curr Protoc Hum Genet Chapter, p.20, 2013.

M. Aglietta, C. Barone, M. B. Sawyer, M. J. Moore, and W. H. Miller, A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer, Ann. Oncol, vol.25, pp.1750-1755, 2014.

J. A. Aguirre-ghiso, Models, mechanisms and clinical evidence for cancer dormancy, Nat. Rev. Cancer, vol.7, pp.834-846, 2007.

M. Ahmadzadeh, L. A. Johnson, B. Heemskerk, J. R. Wunderlich, and M. E. Dudley, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, vol.114, pp.1537-1544, 2009.

L. B. Alexandrov, S. Nik-zainal, D. C. Wedge, S. A. Aparicio, and S. Behjati, Signatures of mutational processes in human cancer, Nature, vol.500, pp.415-421, 2013.

V. Anagnostou, K. N. Smith, P. M. Forde, N. Niknafs, and R. Bhattacharya, Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer, Cancer Discov, vol.7, pp.264-276, 2017.

A. Ardizzoni, L. Boni, M. Tiseo, F. V. Fossella, and J. H. Schiller, Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer : an individual patient data meta-analysis, J. Natl. Cancer Inst, vol.99, pp.847-857, 2007.

Z. Asadzadeh, H. Mohammadi, E. Safarzadeh, M. Hemmatzadeh, and A. Mahdian-shakib, The paradox of Th17 cell functions in tumor immunity, Cell. Immunol, vol.322, pp.15-25, 2017.

P. A. Ascierto, M. Capone, A. M. Grimaldi, D. Mallardo, and E. Simeone, Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations, J Immunother Cancer, vol.7, p.91, 2019.

M. Ashburner, C. A. Ball, J. A. Blake, D. Botstein, and H. Butler, Gene ontology : tool for the unification of biology. The Gene Ontology Consortium, Nat. Genet, vol.25, pp.25-29, 2000.

M. Ayers, J. Lunceford, M. Nebozhyn, E. Murphy, and A. Loboda, IFN-?-related mRNA profile predicts clinical response to PD-1 blockade, J. Clin. Invest, vol.127, pp.2930-2940, 2017.

M. S. Barbee, A. Ogunniyi, T. Z. Horvat, and T. O. Dang, Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology, Ann Pharmacother, vol.49, pp.907-937, 2015.

D. L. Barber, E. J. Wherry, D. Masopust, B. Zhu, and J. P. Allison, Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, vol.439, pp.682-687, 2006.

F. Barlesi, J. Mazieres, J. P. Merlio, D. Debieuvre, and J. Mosser, Routine molecular profiling of patients with advanced non-small-cell lung cancer : results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, vol.387, p.151, 2016.

R. B. Bell, Z. Feng, C. B. Bifulco, R. Leidner, and A. Weinberg, Oral, Head and Neck Oncology and Reconstructive Surgery, pp.314-340, 2018.

,

D. R. Bentley, S. Balasubramanian, H. P. Swerdlow, G. P. Smith, and J. Milton, Accurate whole human genome sequencing using reversible terminator chemistry, Nature, vol.456, pp.53-59, 2008.

F. Binder-foucard, A. Belot, P. Delafosse, L. Remontet, and A. S. Woronoff, Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Partie 1 -Tumeur solides, 2013.

O. Bischof, A. Dejean, and P. Pineau, A review of cellular senescence : friend or foe of tumorigenesis ?, Med Sci, vol.25, pp.153-160, 2009.

P. Boffetta, P. Autier, M. Boniol, P. Boyle, and C. Hill, An estimate of cancers attributable to occupational exposures in France, J. Occup. Environ. Med, vol.52, pp.399-406, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01260430

D. A. Bolotin, S. Poslavsky, I. Mitrophanov, M. Shugay, and I. Z. Mamedov, MiXCR : software for comprehensive adaptive immunity profiling, Nat. Methods, vol.12, pp.380-381, 2015.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, and M. Steins, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.373, pp.1627-1639, 2015.

C. Bosetti, P. Boffetta, and C. La-vecchia, Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers : a quantitative review to, Ann. Oncol, vol.18, pp.431-446, 2005.

J. R. Brahmer, S. S. Tykodi, L. Q. Chow, W. J. Hwu, and S. L. Topalian, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med, vol.366, pp.2455-2465, 2012.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crino, and W. E. Eberhardt, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.373, pp.123-135, 2015.

J. Brahmer, L. Horn, D. Jackman, D. Spigel, and S. Antonia, Abstract CT077 : Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC) : Clinical characteristics of long-term survivors, Cancer Research, vol.77, pp.77-077, 2017.

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, and L. A. Torre, Global cancer statistics 2018 : GLOBO-CAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, vol.68, pp.394-424, 2018.

M. Bruchard, G. Mignot, V. Derangere, F. Chalmin, and A. Chevriaux, Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth, Nat. Med, vol.19, pp.57-64, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00919371

A. Buque, N. Bloy, F. Aranda, F. Castoldi, and A. Eggermont, Trial Watch : Immunomodulatory monoclonal antibodies for oncological indications, Oncoimmunology, vol.4, p.1008814, 2015.

M. J. Butte, M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman, Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses, Immunity, vol.27, pp.111-122, 2007.

J. Campisi and F. Fagagna, Cellular senescence : when bad things happen to good cells, Nat. Rev. Mol. Cell Biol, vol.8, pp.729-740, 2007.

E. Capriotti, R. Calabrese, and R. Casadio, Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information, Bioinformatics, vol.22, p.152, 2006.

L. Carbognin, S. Pilotto, M. Milella, V. Vaccaro, and M. Brunelli, Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1) : Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers, PLoS ONE, vol.10, p.130142, 2015.

D. P. Carbone, M. Reck, L. Paz-ares, B. Creelan, and L. Horn, First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.376, pp.2415-2426, 2017.

D. S. Chen and I. Mellman, Oncology meets immunology : the cancer-immunity cycle, Immunity, vol.39, pp.1-10, 2013.

Y. B. Chen, C. Y. Mu, and J. A. Huang, Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer : a 5-year-follow-up study, Tumori, vol.98, pp.751-755, 2012.

M. Colonna, Epidémiologie du cancer du poumon en France : incidence, mortalité et survie (tendance et situation actuelle), Revue des Maladies Respiratoires Actualités, vol.8, pp.308-318, 2016.

A. Cowppli-bony, Z. Uhry, L. Remontet, A. V. Guizard, and N. Voirin, Survie des personnes atteintes de cancer en France métropolitaine, 1989-2013. Partie 1 -Tumeurs solides, 2016.

T. J. Curiel, S. Wei, H. Dong, X. Alvarez, and P. Cheng, Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity, Nat. Med, vol.9, pp.562-567, 2003.

F. Fagagna, P. M. Reaper, L. Clay-farrace, H. Fiegler, and P. Carr, A DNA damage checkpoint response in telomere-initiated senescence, Nature, vol.426, pp.194-198, 2003.

C. L. Day, D. E. Kaufmann, P. Kiepiela, J. A. Brown, and E. S. Moodley, PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression, Nature, vol.443, pp.350-354, 2006.

L. De-monte, M. Reni, E. Tassi, D. Clavenna, and I. Papa, Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer, J. Exp. Med, vol.208, pp.469-478, 2011.

B. J. Dekosky, G. C. Ippolito, R. P. Deschner, J. J. Lavinder, and Y. Wine, High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire, Nat. Biotechnol, vol.31, pp.166-169, 2013.

F. Delva, P. Andujar, A. Lacourt, P. Brochard, and J. C. Pairon,

, Rev Mal Respir, vol.33, pp.444-459, 2016.

F. Delva, J. Margery, F. Laurent, K. Petitprez, and J. C. Pairon, Medical follow-up of workers exposed to lung carcinogens : French evidence-based and pragmatic recommendations, BMC Public Health, vol.17, p.191, 2017.

D. Maio, M. Lama, N. Morabito, A. Smit, E. F. Georgoulias et al., Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy : a prognostic score from individual data of nine randomised trials, Eur. J. Cancer, vol.46, pp.735-743, 2010.

R. Doll and A. B. Hill, Lung cancer and other causes of death in relation to smoking ; a second report on the mortality of British doctors, Br Med J, vol.2, pp.1071-1081, 1956.

R. Doll, R. Peto, J. Boreham, and I. Sutherland, Mortality in relation to smoking : 50 years' observations on male British doctors, BMJ, vol.328, p.1519, 2004.

H. Dong, S. E. Strome, D. R. Salomao, H. Tamura, and F. Hirano, Tumor-associated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune evasion, Nat. Med, vol.8, pp.793-800, 2002.

G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, Cancer immunoediting : from immunosurveillance to tumor escape, Nat. Immunol, vol.3, pp.991-998, 2002.

G. P. Dunn, L. J. Old, and R. D. Schreiber, The three Es of cancer immunoediting, Annu. Rev. Immunol, vol.22, pp.329-360, 2004.

L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, and J. Vansteenkiste, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR) : a multicentre, open-label, phase 2 randomised controlled trial, Lancet, vol.387, pp.1837-1846, 2016.

P. H. Feng, K. Y. Lee, Y. L. Chang, Y. F. Chan, and L. W. Kuo, CD14(+)S100A9(+) monocytic myeloidderived suppressor cells and their clinical relevance in non-small cell lung cancer, Am. J. Respir. Crit. Care Med, vol.186, pp.1025-1036, 2012.

P. F. Ferrucci, P. A. Ascierto, J. Pigozzo, M. Del-vecchio, and M. Maio, Baseline neutrophils and derived neutrophil-to-lymphocyte ratio : prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann. Oncol, vol.29, p.524, 2018.

K. Fletez-brant, J. ?pidlen, R. R. Brinkman, M. Roederer, and P. K. Chattopadhyay, flowClean : Automated identification and removal of fluorescence anomalies in flow cytometry data, Cytometry A, vol.89, pp.461-471, 2016.

G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, and T. Chernova, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J. Exp. Med, vol.192, pp.1027-1034, 2000.

A. Gagne, W. Enlow, M. A. Pigeon, M. Orain, and S. Turcotte, Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays : Impact of the Architecture Pattern and the Number of Cores, Am. J. Surg. Pathol, vol.42, pp.687-694, 2018.

L. Galluzzi, A. Buque, O. Kepp, L. Zitvogel, and G. Kroemer, Immunogenic cell death in cancer and infectious disease, Nat. Rev. Immunol, vol.17, pp.97-111, 2017.

S. Gandini, E. Botteri, S. Iodice, M. Boniol, and A. B. Lowenfels, Tobacco smoking and cancer : a metaanalysis, Int. J. Cancer, vol.122, pp.155-164, 2008.

A. D. Garg, E. Romano, N. Rufo, and P. Agostinis, Immunogenic versus tolerogenic phagocytosis during anticancer therapy : mechanisms and clinical translation, Cell Death Differ, vol.23, pp.938-951, 2016.

E. B. Garon, N. A. Rizvi, R. Hui, N. Leighl, and A. S. Balmanoukian, Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med, vol.372, pp.2018-2028, 2015.

M. F. Gaumont-leclerc and G. Ferbeyre, Cytokines prevent tumors via a cell senescence mechanism

, Med Sci, vol.25, pp.138-140, 2009.

G. Germano, S. Lamba, G. Rospo, L. Barault, and A. Magri, Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, Nature, vol.552, pp.116-120, 2017.

S. N. Gettinger, L. Horn, L. Gandhi, D. R. Spigel, and S. J. Antonia, Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer, J. Clin. Oncol, vol.33, 2004.

S. N. Gettinger, F. A. Shepherd, S. J. Antonia, J. R. Brahmer, and L. Q. Chow, First-line nivolumab

, ONO-4538) monotherapy in advanced NSCLC : Safety, efficacy, and correlation of outcomes with PD-L1 status, BMS-936558, vol.32, pp.8024-8024, 2014.

C. Gilham, C. Rake, G. Burdett, A. G. Nicholson, and L. Davison, Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden, Occup Environ Med, vol.73, pp.290-299, 2016.

V. Groh, J. Wu, C. Yee, and T. Spies, Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature, vol.419, pp.734-738, 2002.

A. K. Hackshaw, M. R. Law, and N. J. Wald, The accumulated evidence on lung cancer and environmental tobacco smoke, BMJ, vol.315, p.154, 1997.

I. S. Hagemann, C. E. Cottrell, and C. M. Lockwood, Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy, Cancer Genet, vol.206, pp.420-431, 2013.

F. Hahne, N. Lemeur, R. R. Brinkman, B. Ellis, and P. Haaland, flowCore : a Bioconductor package for high throughput flow cytometry, BMC Bioinformatics, vol.10, pp.1471-2105, 2009.
URL : https://hal.archives-ouvertes.fr/inria-00426746

S. V. Hato, A. Khong, I. J. Vries, and W. J. Lesterhuis, Molecular pathways : the immunogenic effects of platinum-based chemotherapeutics, Clin. Cancer Res, vol.20, pp.2831-2837, 2014.

R. B. Hayes, The carcinogenicity of metals in humans, Cancer Causes Control, vol.8, pp.371-385, 1997.

M. D. Hellmann, M. K. Callahan, M. M. Awad, E. Calvo, and P. A. Ascierto, Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer, Cancer Cell, vol.33, pp.853-861, 2018.

M. D. Hellmann, T. Nathanson, H. Rizvi, B. C. Creelan, and F. Sanchez-vega, Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer, Cancer Cell, vol.33, pp.843-852, 2018.

R. S. Herbst, P. Baas, D. W. Kim, E. Felip, and J. L. Perez-gracia, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled trial, Lancet, vol.387, pp.1540-1550, 2016.

F. S. Hodi, V. Chiarion-sileni, R. Gonzalez, J. J. Grob, and P. Rutkowski, Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067) : 4-year outcomes of a multicentre, randomised, phase 3 trial, Lancet Oncol, vol.19, pp.1480-1492, 2018.

B. Howie, A. M. Sherwood, A. D. Berkebile, J. Berka, and R. O. Emerson, High-throughput pairing of T cell receptor ? and ? sequences, Sci Transl Med, vol.7, pp.301-131, 2015.

A. Huang, B. Zhang, B. Wang, F. Zhang, and K. X. Fan, Increased CD14(+)HLA-DR (-/low) myeloidderived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients, Cancer Immunol. Immunother, vol.62, pp.1439-1451, 2013.

J. Hundal, B. M. Carreno, A. A. Petti, G. P. Linette, and O. L. Griffith, pVAC-Seq : A genome-guided in silico approach to identifying tumor neoantigens, Genome Med, vol.8, p.11, 2016.

T. Iarc and . Smoke, Monographs on the Evaluation of Carcinogenic Risks to Humans. Tobacco smole and involuntary smoking, vol.83, pp.51-1187, 2004.

M. Ilie, E. Long-mira, C. Bence, C. Butori, and S. Lassalle, Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances : a potential issue for anti-PD-L1 therapeutic strategies, Ann. Oncol, vol.27, pp.147-153, 2016.

E. Jager, M. Ringhoffer, M. Arand, J. Karbach, and D. Jager, Cytolytic T cell reactivity against melanomaassociated differentiation antigens in peripheral blood of melanoma patients and healthy individuals, Melanoma Res, vol.6, pp.419-425, 1996.

M. Jamal-hanjani, G. A. Wilson, N. Mcgranahan, N. J. Birkbak, and T. B. Watkins, Tracking the Evolution of Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.376, pp.2109-2121, 2017.

K. Jéhannin-ligier, E. Dantony, N. Bossard, F. Molinié, and G. Defossez, Erojection de l'incidence et de la mortalité par cancer en France métropolitaine en 2017. Rapport technique, Santé publique France, vol.122, p.p, 2017.

M. Johansson, D. G. Denardo, and L. M. Coussens, Polarized immune responses differentially regulate cancer development, Immunol. Rev, vol.222, pp.145-154, 2008.

B. E. Johnson and P. A. Janne, Epidermal growth factor receptor mutations in patients with non-small cell lung cancer, Cancer Res, vol.65, p.155, 2005.

C. H. Johnson, M. E. Spilker, L. Goetz, S. N. Peterson, and G. Siuzdak, Metabolite and Microbiome Interplay in Cancer Immunotherapy, Cancer Res, vol.76, pp.6146-6152, 2016.

D. H. Johnson, L. Fehrenbacher, W. F. Novotny, R. S. Herbst, and J. J. Nemunaitis, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J. Clin. Oncol, vol.22, pp.2184-2191, 2004.

M. Kanehisa and S. Goto, KEGG : kyoto encyclopedia of genes and genomes, Nucleic Acids Res, vol.28, pp.27-30, 2000.

S. H. Kaufmann, Immunology's foundation : the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff, Nat. Immunol, vol.9, pp.705-712, 2008.

E. S. Kim, J. E. Kim, M. A. Patel, A. Mangraviti, and J. Ruzevick, Immune Checkpoint Modulators : An Emerging Antiglioma Armamentarium, J Immunol Res, p.4683607, 2016.

S. H. Kim, M. Li, S. Trousil, Y. Zhang, and M. Pasca-di-magliano, Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma, J. Invest. Dermatol, vol.137, pp.1740-1748, 2017.

S. T. Kim, R. Cristescu, A. J. Bass, K. M. Kim, and J. I. Odegaard, Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer, Nat. Med, vol.24, pp.1449-1458, 2018.

M. Kircher, D. M. Witten, P. Jain, B. J. O'roak, and G. M. Cooper, A general framework for estimating the relative pathogenicity of human genetic variants, Nat. Genet, vol.46, pp.310-315, 2014.

C. M. Koebel, W. Vermi, J. B. Swann, N. Zerafa, and S. J. Rodig, Adaptive immunity maintains occult cancer in an equilibrium state, Nature, vol.450, pp.903-907, 2007.

D. M. Kuang, Q. Zhao, C. Peng, J. Xu, and J. P. Zhang, Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1, J. Exp. Med, vol.206, pp.1327-1337, 2009.

T. Kuilman and D. S. Peeper, Senescence-messaging secretome : SMS-ing cellular stress, Nat. Rev. Cancer, vol.9, pp.81-94, 2009.

D. T. Le, J. N. Durham, K. N. Smith, H. Wang, and B. R. Bartlett, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, vol.357, pp.409-413, 2017.

D. T. Le, J. N. Uram, H. Wang, B. R. Bartlett, and H. Kemberling, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N. Engl. J. Med, vol.372, pp.2509-2520, 2015.

K. Leuraud, M. Schnelzer, L. Tomasek, N. Hunter, and M. Timarche, Radon, smoking and lung cancer risk : results of a joint analysis of three European case-control studies among uranium miners, Radiat. Res, vol.176, pp.375-387, 2011.

L. Liu, Y. Li, S. Li, N. Hu, and Y. He, Comparison of next-generation sequencing systems, J. Biomed. Biotechnol, vol.2012, p.251364, 2012.

D. Loomis, W. Huang, and G. Chen, The International Agency for Research on Cancer (IARC) evaluation of the carcinogenicity of outdoor air pollution : focus on China, Chin J Cancer, vol.33, pp.189-196, 2014.

A. Lopez-chavez, T. Young, S. Fages, L. Leon, and J. H. Schiller, Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study : results of an exploratory analysis, J Thorac Oncol, vol.7, pp.1707-1712, 2012.

S. W. Lowe, E. Cepero, and G. Evan, Intrinsic tumour suppression, Nature, vol.432, p.156, 2004.

J. H. Lubin, Radon and lung cancer risk : a joint analysis of 11 underground miners studies, National Institutes of Health, 1994.

C. Lundegaard, K. Lamberth, M. Harndahl, S. Buus, and O. Lund, NetMHC-3.0 : accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11, Nucleic Acids Res, vol.36, pp.509-512, 2008.

M. Luo and L. Fu, The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis : some chemotherapeutical drugs may finally work through immune response, Oncotarget, vol.7, pp.29794-29803, 2016.

T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, and R. A. Okimoto, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med, vol.350, pp.2129-2139, 2004.

M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, and S. Oizumi, Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR, N. Engl. J. Med, vol.362, pp.2380-2388, 2010.

J. Malhotra, M. Malvezzi, E. Negri, C. La-vecchia, and P. Boffetta, Risk factors for lung cancer worldwide, Eur. Respir. J, vol.48, pp.889-902, 2016.

A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, Cancer-related inflammation, Nature, vol.454, pp.436-444, 2008.

M. Manuel, O. Tredan, T. Bachelot, G. Clapisson, and A. Courtier, Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients, Oncoimmunology, vol.1, pp.432-440, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00724448

P. Marino, R. Touzani, L. Perrier, E. Rouleau, and D. S. Kossi, Correction : Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice : a nationwide French study, Eur. J. Hum. Genet, vol.26, pp.1396-1397, 2018.

A. Martens, K. Wistuba-hamprecht, M. Geukes-foppen, J. Yuan, and M. A. Postow, Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab, Clin. Cancer Res, vol.22, pp.2908-2918, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01409624

I. Martins, O. Kepp, F. Schlemmer, S. Adjemian, and M. Tailler, Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress, Oncogene, vol.30, pp.1147-1158, 2011.

S. Mastaglio, E. Wong, T. Perera, J. Ripley, and P. Blombery, Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy, Blood Adv, vol.2, pp.335-346, 2018.

T. R. Matos, M. A. Rie, and M. B. Teunissen, Research Techniques Made Simple : High-Throughput Sequencing of the T-Cell Receptor, J. Invest. Dermatol, vol.137, pp.131-138, 2017.

H. Matsushita, M. D. Vesely, D. C. Koboldt, C. G. Rickert, and R. Uppaluri, Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting, Nature, vol.482, pp.400-404, 2012.

C. Meldrum, M. A. Doyle, and R. W. Tothill, Next-generation sequencing for cancer diagnostics : a practical perspective, Clin Biochem Rev, vol.32, pp.177-195, 2011.

M. L. Metzker, Emerging technologies in DNA sequencing, Genome Res, vol.15, pp.1767-1776, 2005.

D. Miao, C. A. Margolis, N. I. Vokes, D. Liu, and A. Taylor-weiner, Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors, Nat. Genet, vol.50, pp.1271-1281, 2018.

D. Mittal, M. M. Gubin, R. D. Schreiber, and M. J. Smyth, New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape, Curr. Opin. Immunol, vol.27, pp.16-25, 2014.

T. S. Mok, Y. L. Wu, S. Thongprasert, C. H. Yang, and D. T. Chu, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N. Engl. J. Med, vol.361, p.157, 2009.

K. W. Mouw, M. S. Goldberg, P. A. Konstantinopoulos, and A. D. D'andrea, DNA Damage and Repair Biomarkers of Immunotherapy Response, Cancer Discov, vol.7, pp.675-693, 2017.

C. Y. Mu, J. A. Huang, Y. Chen, C. Chen, and X. G. Zhang, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Med. Oncol, vol.28, pp.682-688, 2011.

P. C. Ng and S. Henikoff, SIFT : Predicting amino acid changes that affect protein function, Nucleic Acids Res, vol.31, pp.3812-3814, 2003.

C. J. Nirschl and C. G. Drake, Molecular pathways : coexpression of immune checkpoint molecules : signaling pathways and implications for cancer immunotherapy, Clin. Cancer Res, vol.19, pp.4917-4924, 2013.

U. D. Health and . H. Services, The Health Consequences of Smoking : 50 Years of Progress. A Report of the Surgeon General, Centers for Disease Control and Prevention, 2014.

A. C. Olsson, P. Gustavsson, H. Kromhout, S. Peters, and R. Vermeulen, Exposure to diesel motor exhaust and lung cancer risk in a pooled analysis from case-control studies in Europe and Canada, Am. J. Respir. Crit. Care Med, vol.183, pp.941-948, 2011.

A. Orillion, A. Hashimoto, N. Damayanti, L. Shen, and R. Adelaiye-ogala, Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma, Clin. Cancer Res, vol.23, pp.5187-5201, 2017.

S. H. Ou, J. S. Ahn, L. De-petris, R. Govindan, and J. C. Yang, Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer : A Phase II Global Study, J. Clin. Oncol, vol.34, pp.661-668, 2016.

J. G. Paez, P. A. Janne, J. C. Lee, S. Tracy, and H. Greulich, EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy, Science, vol.304, pp.1497-1500, 2004.

C. Paolillo, E. Londin, and P. Fortina, Next generation sequencing in cancer : opportunities and challenges for precision cancer medicine. Scand, J. Clin. Lab. Invest. Suppl, vol.245, pp.84-91, 2016.

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, vol.12, pp.252-264, 2012.

R. V. Parry, J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, and I. Braunstein, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol. Cell. Biol, vol.25, pp.9543-9553, 2005.

C. Pfirschke, C. Engblom, S. Rickelt, V. Cortez-retamozo, and C. Garris, Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy, Immunity, vol.44, pp.343-354, 2016.

M. A. Postow, M. Manuel, P. Wong, J. Yuan, and Z. Dong, Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma, J Immunother Cancer, vol.3, p.23, 2015.

J. L. Pujol, F. Barlesi, and J. P. Daures, Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based ? A meta-analysis of phase III randomized trials, Lung Cancer, vol.51, pp.335-345, 2006.

O. Raaschou-nielsen, Z. J. Andersen, R. Beelen, E. Samoli, and M. Stafoggia, Air pollution and lung cancer incidence in 17 European cohorts : prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE), Lancet Oncol, vol.14, pp.813-822, 2013.

S. Radoja, T. D. Rao, D. Hillman, and A. B. Frey, Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo, J. Immunol, vol.164, pp.2619-2628, 2000.

C. Rancoule, A. Vallard, J. B. Guy, S. Espenel, and S. Sauvaigo,

, Bull Cancer, vol.104, pp.962-970, 2017.

M. Reck, D. Rodriguez-abreu, A. G. Robinson, R. Hui, and T. Cs-?szi, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.375, pp.1823-1833, 2016.

M. Reck, J. Pawel, P. Zatloukal, R. Ramlau, and V. Gorbounova, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer : AVAil, J. Clin. Oncol, vol.27, pp.1227-1234, 2009.

N. Riaz, J. J. Havel, V. Makarov, A. Desrichard, and W. J. Urba, Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab, Cell, vol.171, pp.934-949, 2017.

A. Ribas, Tumor immunotherapy directed at PD-1, N. Engl. J. Med, vol.366, pp.2517-2519, 2012.

H. Rizvi, F. Sanchez-vega, K. La, W. Chatila, and P. Jonsson, Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing, J. Clin. Oncol, vol.36, pp.633-641, 2018.

N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, and V. Makarov, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, pp.124-128, 2015.

N. A. Rizvi, J. Mazieres, D. Planchard, T. E. Stinchcombe, and G. K. Dy, Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063) : a phase 2, single-arm trial, Lancet Oncol, vol.16, pp.257-265, 2015.

R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, and B. Massuti, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC) : a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, vol.13, pp.239-246, 2012.

R. Rosenthal, N. Mcgranahan, J. Herrero, B. S. Taylor, and C. Swanton, DeconstructSigs : delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution, Genome Biol, vol.17, p.31, 2016.

M. Rota, C. Bosetti, S. Boccia, P. Boffetta, and C. La-vecchia, Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers : an updated systematic review and a metaanalysis to, Arch. Toxicol, vol.88, pp.1479-1490, 2014.

B. Routy, E. Le-chatelier, L. Derosa, C. P. Duong, and M. T. Alou, Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science, vol.359, pp.91-97, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02126484

S. Roychowdhury and A. M. Chinnaiyan, Translating genomics for precision cancer medicine, Annu Rev Genomics Hum Genet, vol.15, pp.395-415, 2014.

C. E. Rudd, A. Taylor, and H. Schneider, CD28 and CTLA-4 coreceptor expression and signal transduction, Immunol. Rev, vol.229, pp.12-26, 2009.

Y. Sakamoto, L. Xu, M. Seki, T. T. Yokoyama, and M. Kasahara, Long read sequencing reveals a novel class of structural aberrations in cancers : identification and characterization of cancerous local amplifications, 2019.

R. M. Samstein, C. H. Lee, A. N. Shoushtari, M. D. Hellmann, and R. Shen, Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat. Genet, vol.51, pp.202-206, 2019.

J. H. Schiller, D. Harrington, C. P. Belani, C. Langer, and A. Sandler, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N. Engl. J. Med, vol.346, pp.92-98, 2002.

R. D. Schreiber, L. J. Old, and M. J. Smyth, Cancer immunoediting : integrating immunity's roles in cancer suppression and promotion, Science, vol.331, p.159, 2011.

T. N. Schumacher and R. D. Schreiber, Neoantigens in cancer immunotherapy, Science, vol.348, pp.69-74, 2015.

L. H. Schwartz, S. Litiere, E. Vries, R. Ford, and S. Gwyther, RECIST 1.1-Update and clarification : From the RECIST committee, Eur. J. Cancer, vol.62, pp.132-137, 2016.

A. Seidler, S. Jahnichen, J. Hegewald, A. Fishta, and O. Krug, Systematic review and quantification of respiratory cancer risk for occupational exposure to hexavalent chromium, Int Arch Occup Environ Health, vol.86, pp.943-955, 2013.

K. S. Sfanos, T. C. Bruno, A. K. Meeker, A. M. De-marzo, and W. B. Isaacs, Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+, Prostate, vol.69, pp.1694-1703, 2009.

P. Sharma and J. P. Allison, The future of immune checkpoint therapy, Science, vol.348, pp.56-61, 2015.

A. T. Shaw, D. W. Kim, R. Mehra, D. S. Tan, and E. Felip, Ceritinib in ALK-rearranged non-small-cell lung cancer, N. Engl. J. Med, vol.370, pp.1189-1197, 2014.

A. T. Shaw, D. W. Kim, K. Nakagawa, T. Seto, and L. Crino, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N. Engl. J. Med, vol.368, pp.2385-2394, 2013.

A. T. Shaw, B. Y. Yeap, B. J. Solomon, G. J. Riely, and J. Gainor, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement : a retrospective analysis, Lancet Oncol, vol.12, pp.1004-1012, 2011.

K. I. Al-shibli, T. Donnem, S. Al-saad, M. Persson, and R. M. Bremnes, Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer, Clin. Cancer Res, vol.14, pp.5220-5227, 2008.

A. C. Smart, C. A. Margolis, H. Pimentel, M. X. He, and D. Miao, Intron retention is a source of neoepitopes in cancer, Nat. Biotechnol, vol.36, pp.1056-1058, 2018.

M. J. Smyth, G. P. Dunn, and R. D. Schreiber, Cancer immunosurveillance and immunoediting : the roles of immunity in suppressing tumor development and shaping tumor immunogenicity, Adv. Immunol, vol.90, pp.1-50, 2006.

A. Snyder, T. Nathanson, S. A. Funt, A. Ahuja, and J. Buros-novik, Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer : An exploratory multiomic analysis, PLoS Med, vol.14, p.1002309, 2017.

M. A. Socinski, R. M. Jotte, F. Cappuzzo, F. Orlandi, and D. Stroyakovskiy, Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N. Engl. J. Med, vol.378, pp.2288-2301, 2018.

M. Soda, Y. L. Choi, M. Enomoto, S. Takada, and Y. Yamashita, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, vol.448, pp.561-566, 2007.

B. J. Solomon, T. Mok, D. W. Kim, Y. L. Wu, and K. Nakagawa, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N. Engl. J. Med, vol.371, pp.2167-2177, 2014.

J. C. Soria, A. Marabelle, J. R. Brahmer, and S. Gettinger, Immune checkpoint modulation for non-small cell lung cancer, Clin. Cancer Res, vol.21, pp.2256-2262, 2015.

R. M. Steinman, Decisions about dendritic cells : past, present, and future, Annu. Rev. Immunol, vol.30, pp.1-22, 2012.

I. Sullivan and D. Planchard, ALK inhibitors in non-small cell lung cancer : the latest evidence and developments, Ther Adv Med Oncol, vol.8, pp.32-47, 2016.

C. Sun, R. Mezzadra, and T. N. Schumacher, Regulation and Function of the PD-L1 Checkpoint, Immunity, vol.48, pp.434-452, 2018.

J. Sunshine and J. M. Taube, PD-1/PD-L1 inhibitors, Curr Opin Pharmacol, vol.23, pp.32-38, 2015.

A. Suzuki, M. Suzuki, J. Mizushima-sugano, M. C. Frith, and W. Makalowski, Sequencing and phasing cancer mutations in lung cancers using a long-read portable sequencer, DNA Res, vol.24, p.160, 2017.

M. Sznol and L. Chen, Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer, Clin. Cancer Res, vol.19, pp.1021-1034, 2013.

E. Tappeiner, F. Finotello, P. Charoentong, C. Mayer, and D. Rieder, TIminer : NGS data mining pipeline for cancer immunology and immunotherapy, Bioinformatics, vol.33, pp.3140-3141, 2017.

M. W. Teng, S. F. Ngiow, A. Ribas, and M. J. Smyth, Classifying Cancers Based on T-cell Infiltration and PD-L1, Cancer Res, vol.75, pp.2139-2145, 2015.

M. Y. Teo, K. Seier, I. Ostrovnaya, A. M. Regazzi, and B. E. Kania, Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers, J. Clin. Oncol, vol.36, pp.1685-1694, 2018.

T. Tokito, K. Azuma, A. Kawahara, H. Ishii, and K. Yamada, Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy, Eur. J. Cancer, vol.55, pp.7-14, 2016.

S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, and D. C. Smith, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med, vol.366, pp.2443-2454, 2012.

J. Tredaniel, P. Boffetta, R. Saracci, and A. Hirsch, Exposure to environmental tobacco smoke and risk of lung cancer : the epidemiological evidence, Eur. Respir. J, vol.7, pp.1877-1888, 1994.

C. T. Tsoi and L. A. Tse, Professional drivers and lung cancer : a systematic review and meta-analysis, Occup Environ Med, vol.69, pp.831-836, 2012.

P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, and E. J. Taylor, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, pp.568-571, 2014.

C. Turnbull, Introducing whole-genome sequencing into routine cancer care : the, Genomics England, vol.100

, Genomes Project. Ann. Oncol, vol.29, pp.784-787, 2018.

A. D. Tyler, L. Mataseje, C. J. Urfano, L. Schmidt, and K. S. Antonation, Evaluation of Oxford Nanopore's MinION Sequencing Device for Microbial Whole, Genome Sequencing Applications. Sci Rep, vol.8, p.10931, 2018.

G. A. Van-der-auwera, M. O. Carneiro, C. Hartl, R. Poplin, and G. Del-angel, From FastQ data to high confidence variant calls : the Genome Analysis Toolkit best practices pipeline, Curr Protoc Bioinformatics, vol.43, pp.1-33, 2013.

J. Vincent, G. Mignot, F. Chalmin, S. Ladoire, and M. Bruchard, 5-Fluorouracil selectively kills tumorassociated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity, Cancer Res, vol.70, pp.3052-3061, 2010.

B. Wallden, I. Pekker, S. Popa, N. Dowidar, and A. Sullivan, Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System, Journal of Clinical Oncology, vol.34, pp.3034-3034, 2016.

Q. Wang and X. Wu, Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment, Int. Immunopharmacol, vol.46, pp.210-219, 2017.

S. Wang, M. Jia, Z. He, and X. S. Liu, APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer, Oncogene, vol.37, pp.3924-3936, 2018.

R. Weber, V. Fleming, X. Hu, V. Nagibin, and C. Groth, Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors, Front Immunol, vol.9, p.1310, 2018.

B. Weide, A. Martens, J. C. Hassel, C. Berking, and M. A. Postow, Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab, Clin. Cancer Res, vol.22, p.161, 2016.

D. Wraith and K. Mengersen, A Bayesian approach to assess interaction between known risk factors : the risk of lung cancer from exposure to asbestos and smoking, Stat Methods Med Res, vol.17, pp.171-189, 2008.

Y. M. Wu, M. Cie-?lik, R. J. Lonigro, P. Vats, and M. A. Reimers, Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer, Cell, vol.173, pp.1770-1782, 2018.

Y. Yamauchi, S. Safi, C. Blattner, A. Rathinasamy, and L. Umansky, Circulating and Tumor Myeloidderived Suppressor Cells in Resectable Non-Small Cell Lung Cancer, Am. J. Respir. Crit. Care Med, vol.198, pp.777-787, 2018.

M. Yarchoan, B. A. Johnson, E. R. Lutz, D. A. Laheru, and E. M. Jaffee, Targeting neoantigens to augment antitumour immunity, Nat. Rev. Cancer, vol.17, pp.209-222, 2017.

Z. Zhong, E. Sanchez-lopez, and M. Karin, Autophagy, Inflammation, and Immunity : A Troika Governing Cancer and Its Treatment, Cell, vol.166, pp.288-298, 2016.

L. Zitvogel, A. Tesniere, and G. Kroemer, Cancer despite immunosurveillance : immunoselection and immunosubversion, Nat. Rev. Immunol, vol.6, pp.715-727, 2006.

W. Zou and L. Chen, Inhibitory B7-family molecules in the tumour microenvironment, Nat. Rev. Immunol, vol.8, pp.467-477, 2008.

M. Devaux, L. Gerard, C. Richard, L. Bengrine-lefevre, and J. Vincent, Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer, World J Clin Oncol, vol.10, pp.75-85, 2019.

A. Elkrief, L. El-raichani, C. Richard, M. Messaoudene, and W. Belkaid, Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors, Oncoimmunology, vol.8, p.1568812, 2019.

M. Grapin, C. Richard, E. Limagne, R. Boidot, and V. Morgand, Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT : a promising new combination, J Immunother Cancer, vol.7, p.160, 2019.

E. Limagne, C. Richard, M. Thibaudin, J. D. Fumet, and C. Truntzer, Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients, Oncoimmunology, vol.8, p.1564505, 2019.

C. Richard, J. D. Fumet, S. Chevrier, V. Derangere, and F. Ledys, Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients, Clin. Cancer Res, vol.25, pp.957-966, 2019.

A. Aarnink, C. Richard, C. Truntzer, J. Vincent, and L. Bengrine, Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma, Oncotarget, vol.9, pp.25617-25629, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01821601

J. D. Fumet, C. Richard, F. Ledys, Q. Klopfenstein, and P. Joubert, Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy, Br. J. Cancer, vol.119, pp.950-960, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01980112

N. Isambert, A. Hervieu, C. Rebe, A. Hennequin, and C. Borg, Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU) : a single-arm phase 2 study, Oncoimmunology, vol.7, p.1474319, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01880140

C. Richard, J. Niogret, R. Boidot, and F. Ghiringhelli, EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma, World J Gastrointest Oncol, vol.10, pp.103-107, 2018.

E. Humblin, M. Thibaudin, F. Chalmin, V. Derangere, and E. Limagne, IRF8-dependent molecular complexes control the Th9 transcriptional program, Nat Commun, vol.8, p.2085, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01682219

C. G. Kaderbhai, C. Richard, J. D. Fumet, A. Aarnink, and S. Ortiz-cuaran, Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer, Oncoimmunology, vol.6, p.1339856, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01694057

C. Kaderbhai, C. Richard, J. D. Fumet, A. Aarnink, and P. Foucher, Antibiotic Use Does Not Appear to Influence Response to Nivolumab, Anticancer Res, vol.37, p.163, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01545832

F. Ghiringhelli, C. Richard, S. Chevrier, F. Vegran, and R. Boidot, Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein, World J. Gastroenterol, vol.22, pp.10680-10686, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01452654

, Communications affichées

M. Grapin, E. Limagne, C. Richard, R. Boidot, and M. Thibaudin, Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT : a promising combination. Abstract PV-0537, Présenté au 38ème congrès annuel de l'ESTRO, 2019.

S. Medjebar, C. Richard, J. D. Fumet, J. Malo, and B. Routy, Angiotensin-Converting Enzyme Inhibitor Is Associated with Decreased Survival in NSCLC Patients Treated with PD-1 Checkpoint Blockers, Abstract #2389, 2019.

C. Richard, A. Elkrief, J. Malo, L. Cvetkovic, and M. Florescu, Body Mass Index and Age Do Not Influence Survival in Patients with Lung Cancers Treated with PD1/PDL1 Immune Checkpoint Inhibitors. Abstract #2333, 2019.

C. Richard, S. Fumet, V. Derangere, R. Boidot, P. Truntzer et al., An Interactive Interface for Prediction of Anti-PD-1 Efficacy in Lung Cancer Patients. Abstract #2460, 2019.

J. D. Fumet, C. Richard, F. Ledys, Q. Klopfenstein, and C. Truntzer, CD8 and PD-L1 determination in lung tumor tissue as prognostic biomarker and a predictive marjer of anti-PD-1 efficacy. Abstract #3021, 2018.

E. Limagne, C. Richard, M. Thibaudin, J. D. Fumet, and C. Truntzer, La voie TIM-3/Galectine-9 et les MDSC monocytaires (mMDSC) sont impliquées dans la résistance au Nivolumab dans les cancers bronchiques de stade III/IV. Abstract SP11-44, 2018.

C. Richard, J. D. Fumet, S. Chevrier, V. Derangere, and F. Ledys, Exome Analysis to Reveal Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. Abstract #9044, Présenté au congrès annuel de l, 2018.

C. Richard, J. D. Fumet, S. Chevrier, V. Derangere, and F. Ledys, Exome Analysis to Reveal Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. Abstract P2, Présenté au congrès WIN Symposium, vol.22, 2018.

C. Richard, J. D. Fumet, S. Chevrier, V. Derangere, and F. Ledys, Exome Analysis to Reveal Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients, Présenté au Forum des Jeunes Chercheurs, vol.54, 2018.

C. G. Kaderbhai, C. Richard, J. D. Fumet, A. Aarnink, and S. Ortiz-cuaran, Response to firstline chemotherapy regimen to predict efficacy of nivolumab in lung cancer. Abstract #3026, Présenté au congrès annuel de l, 2017.